glp-1 heart benefits Receptor Agonists in Failure Management GLP-1 Agonists in Cardiovascular Diseases:

Most GLP-1 receptor agonists (except exenatide formulations) carry an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Nights become more solid

Plan sponsors are currently facing critical decisions regarding GLP-1 medications which require balancing costs, member health benefits, and evolving medication landscapes

Injectable wins

Wang B-H, Ou-Yang J-P

(Revised 8/31/2018) A: PPS networks were submitted via the DSRIP Network Tool for the purposes of calculating attribution for valuation and later, attribution for performance